EQ Insider Trading
Insider Ownership Percentage: 31.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $220,107.03
Equillium Share Price & Price History
Current Price: $1.27
Price Change: ▲ Price Increase of +0.085 (7.20%)
As of 01/23/2026 02:10 PM ET
Equillium Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/8/2026 | Penny Tom | Insider | Sell | 6,533 | $1.29 | $8,427.57 | | |
| 12/23/2025 | Christine Zedelmayer | COO | Sell | 100,000 | $1.50 | $150,000.00 | 91,444 | |
| 12/15/2025 | Christine Zedelmayer | COO | Sell | 11,900 | $1.31 | $15,589.00 | 91,444 | |
| 12/12/2025 | Christine Zedelmayer | COO | Sell | 23,804 | $1.34 | $31,897.36 | 103,344 | |
| 11/25/2025 | Christine Zedelmayer | COO | Sell | 8,098 | $0.95 | $7,693.10 | 127,148 | |
| 1/23/2025 | Jason A Keyes | CFO | Sell | 10,000 | $0.65 | $6,500.00 | 37,720 | |
| 11/14/2024 | Jason A Keyes | CFO | Sell | 10,000 | $0.70 | $7,000.00 | 47,720 | |
| 10/28/2024 | Christine Zedelmayer | COO | Sell | 15,000 | $1.25 | $18,750.00 | 135,246 | |
| 10/28/2024 | Penny Tom | Insider | Sell | 2,835 | $1.25 | $3,543.75 | 6,533 | |
| 10/25/2024 | Penny Tom | Insider | Sell | 683 | $1.25 | $853.75 | 9,368 | |
| 9/26/2024 | Jason A Keyes | CFO | Sell | 10,000 | $0.81 | $8,100.00 | 57,720 | |
| 9/16/2024 | Penny Tom | Insider | Sell | 38,806 | $0.85 | $32,985.10 | 10,051 | |
| 7/16/2024 | Jason A Keyes | CFO | Sell | 10,000 | $0.87 | $8,700.00 | 67,720 | |
Equillium Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 1/16/2026 | Aberdeen Group plc | 2,366,688 | $3.67M | 0.0% | +523.6% | 3.887% |  |
| 12/15/2025 | Hudson Bay Capital Management LP | 278,538 | $0.40M | 0.0% | N/A | 0.457% |  |
| 12/1/2025 | Cantor Fitzgerald L. P. | 425,000 | $0.61M | 0.0% | N/A | 0.698% |  |
| 11/17/2025 | Woodline Partners LP | 3,508,771 | $5.02M | 0.0% | N/A | 5.762% |  |
| 11/17/2025 | Millennium Management LLC | 24,356 | $35K | 0.0% | N/A | 0.040% |  |
| 11/17/2025 | Cantor Fitzgerald L. P. | 425,000 | $0.61M | 0.0% | N/A | 0.698% |  |
| 11/17/2025 | Boothbay Fund Management LLC | 121,953 | $0.17M | 0.0% | N/A | 0.200% |  |
| 11/14/2025 | Schonfeld Strategic Advisors LLC | 124,823 | $0.18M | 0.0% | N/A | 0.210% |  |
| 11/14/2025 | Virtu Financial LLC | 23,779 | $34K | 0.0% | +133.4% | 0.040% |  |
| 11/14/2025 | ADAR1 Capital Management LLC | 5,559,988 | $7.95M | 0.7% | N/A | 9.345% |  |
| 11/14/2025 | Two Sigma Investments LP | 133,004 | $0.19M | 0.0% | N/A | 0.224% |  |
| 11/10/2025 | Persistent Asset Partners Ltd | 68,991 | $99K | 0.1% | N/A | 0.116% |  |
| 11/7/2025 | Vanguard Group Inc. | 1,313,946 | $1.88M | 0.0% | +59.4% | 2.208% |  |
| 11/7/2025 | Aberdeen Group plc | 379,526 | $0.54M | 0.0% | N/A | 0.638% |  |
| 2/13/2025 | Renaissance Technologies LLC | 261,400 | $0.20M | 0.0% | -18.6% | 0.738% |  |
| 2/12/2025 | Takeda Pharmaceutical Co. Ltd. | 1,824,977 | $1.37M | 5.2% | N/A | 5.151% |  |
| 2/11/2025 | DCF Advisers LLC | 62,947 | $47K | 0.0% | +91.0% | 0.178% |  |
| 8/9/2024 | Renaissance Technologies LLC | 300,400 | $0.21M | 0.0% | +43.6% | 0.852% |  |
| 5/10/2024 | Acadian Asset Management LLC | 108,691 | $0.25M | 0.0% | N/A | 0.308% |  |
| 2/12/2024 | Decheng Capital LLC | 4,447,308 | $3.22M | 0.9% | N/A | 12.663% |  |
| 8/9/2023 | DCF Advisers LLC | 111,623 | $84K | 0.0% | -28.9% | 0.324% |  |
| 5/2/2023 | Victory Capital Management Inc. | 345,861 | $0.25M | 0.0% | -89.2% | 1.005% |  |
| 2/14/2023 | True North Advisors LLC | 265,370 | $0.27M | 0.1% | +50.5% | 0.771% |  |
| 2/13/2023 | Callan Capital LLC | 103,688 | $0.11M | 0.0% | N/A | 0.301% |  |
| 2/9/2023 | Victory Capital Management Inc. | 3,198,745 | $3.52M | 0.0% | -12.4% | 9.296% |  |
| 1/24/2023 | Capital CS Group LLC | 24,000 | $25K | 0.0% | N/A | 0.070% |  |
| 11/7/2022 | Virtu Financial LLC | 24,141 | $54K | 0.0% | N/A | 0.070% |  |
| 11/2/2022 | Victory Capital Management Inc. | 3,651,084 | $8.11M | 0.0% | +2.1% | 10.651% |  |
| 8/11/2022 | DCF Advisers LLC | 114,027 | $0.23M | 0.1% | -31.2% | 0.333% |  |
| 8/1/2022 | Victory Capital Management Inc. | 3,577,211 | $7.30M | 0.0% | -0.6% | 10.436% |  |
| 5/16/2022 | Cota Capital Management LLC | 562,278 | $1.77M | 0.4% | N/A | 1.640% |  |
| 5/10/2022 | Decheng Capital Management III Cayman LLC | 4,447,308 | $14.01M | 4.3% | N/A | 12.975% |  |
| 5/4/2022 | Victory Capital Management Inc. | 3,597,799 | $11.33M | 0.0% | +8.2% | 10.495% |  |
| 2/15/2022 | Samsara BioCapital LLC | 615,541 | $2.32M | 0.5% | -16.6% | 2.094% |  |
| 2/7/2022 | Victory Capital Management Inc. | 3,325,050 | $12.47M | 0.0% | +4.9% | 11.313% |  |
| 11/16/2021 | Two Sigma Securities LLC | 83,948 | $0.57M | 0.0% | N/A | 0.286% |  |
| 11/12/2021 | Geode Capital Management LLC | 154,185 | $1.05M | 0.0% | +2.4% | 0.525% |  |
Data available starting January 2016
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Read More on Equillium
Volume
322,138 shs
Average Volume
530,230 shs
Market Capitalization
$77.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.86
Who are the company insiders with the largest holdings of Equillium?
Who are the major institutional investors of Equillium?
Which institutional investors are buying Equillium stock?
In the previous quarter, EQ stock was purchased by institutional investors including:
- Aberdeen Group plc